UniQure Huntington's Drug Faces FDA Setback, Shares Drop 19%
UniQure stock tumbles as FDA says AMT-130 gene therapy data insufficient for approval. Company seeks urgent Q1 2026 meeting to advance Huntington's disease treatment.
/ 433 items
#Healthcare↓
Hims & Hers Expands to Canada with Weight Loss Focus
US telehealth giant Hims & Hers enters Canadian market through Livewell acquisition, targeting obesity crisis with affordable digital healthcare and upcoming generic semaglutide access.
Goldman Sachs Downgrades Halozyme to Sell
HALO faces a post-2030 royalty cliff; Goldman Sachs cuts rating to Sell with $56 target, citing long-term revenue risks.
Goldman Sachs Initiates Sell Rating on MBX Biosciences
Goldman Sachs starts coverage of MBX Biosciences with a Sell rating and $18 price target, citing cautious outlook ahead of key trial data in 2026.
Needham Starts Coverage on Solid Biosciences with Buy Rating
Needham initiates Buy on Solid Biosciences with $16 target, highlighting potential of SGT-003 gene therapy amid concerns over Sarepta’s Elevidys safety.
Axogen Stock Soars on FDA Approval for Nerve Repair Treatment
Axogen shares jumped 7% in premarket trading after FDA approved its Avance nerve repair treatment for adults and children, strengthening its market position.